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A  fundamental component of the inflammatory response is an increase in 
vascular permeability. The change in permeability is mediated in a number of 
different ways,  depending  at  least  partly upon  the  nature  of  the  injurious 
stimulus.  Several mechanisms  have been suggested  to explain  the increased 
vascular permeability which accompanies antigen-antibody reactions, including 
the local release of histamine (1), the activation of a specific plasma permeability 
factor  (2),  and  the  evolution  of  one  or  more  toxic  agents,  designated 
as anaphylatoxins (3), which in turn may effect a release of such pharmacologic 
mediators of inflammation as histamine and serotonin. 
The participation of complement in  the pathogenesis of inflammation has 
been suggested on the basis of studies of passive cutaneous anaphylaxis in the 
rat  (4--6), but data inconsistent with this view have been published recently 
(6 a). The inflammatory response induced by the intraperitoneal injection of 
human plasma in rats also seems dependent upon the presence of complement 
(7). The precise manner in which complement may mediate an enhancement of 
vascular permeability is unknown, although it appears to be a requirement for 
generation of anaphylatoxin in certain experimental systems (6). 
Considerable progress has  been made in recent years in knowledge of the 
mechanism of action of complement in a variety of immune reactions. It is now 
well established that the interaction of antigen-antibody complexes with the 
first  component  of  complement  (C'I)  results  in  activation  of  an  enzyme, 
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variously  designated  as  Ctl  esterase,  activated  Cq,  converted  C'I,  or  Cqa 
(8-13).  The active enzyme, capable of hydrolyzing selected amino acid esters 
and  of  inactivating  the  fourth  (C'4)  and  second  (C'2)  components  of 
complement  in  solution,  is  a  functional  requirement  for  the  interaction  of 
antigen-antibody-Cq complexes with C'4 and C~2 (14,  15). A naturally occur- 
ring inhibitor in human serum, a  heat-labile a-globulin, has been purified and 
is capable under appropriate conditions of blocking both the esterolytic activity 
of Cq esterase and its interaction with C'4 and Ct2 (16--21). Human Crl esterase 
has recently been highly purified (22) and shown to function as a component of 
complement in immune hemolysis (23). 
Since the generation of Cq  esterase  is an early event in the mechanism of 
action of complement, it would be predicted that if complement  is a  mediator 
of  the  inflammatory  response  induced  by  antigen-antibody  reactions  then 
purified Crl esterase might be capable of inducing such a response. The present 
investigation was undertaken to test this hypothesis. The results to be presented 
demonstrate  that  enhancement  of vascular  permeability  in  guinea  pig  skin 
may in fact be effected by purified human  Cq  esterase.  This phenomenon is 
prevented  by  purified  serum  inhibitor  of  Crl  esterase  and  other  agents  or 
procedures which block or inactivate enzymatic activity. Although the observa- 
tions to be reported are consistent with the possibility that histamine may be 
the final mediator of enhanced vascular permeability induced by Cq esterase, 
direct evidence is not available and the mechanism of the reaction is not yet 
known. 
Materials and Methods 
Vascular permeability was tested  using the technique  of Miles and Wilhelm (24). Non- 
inbred  albino  guinea pigs of either  sex, usually  weighing between 400 and 450 gin,  were 
depilated and injected intravenously with 1.2 ml per kg of body weight of a 5 per cent solution 
of pontamine  sky blue  6  X  (E.  I.  DuPont  de  Nemours  and  Company,  Wilmington)  in 
0.075 ~ pyrogen-free sodium chloride solution. The solutions to be tested were then injected 
intracutaneously  into the dorsum of the guinea pig in a volume of 0.1 ml, using No. 26, 1/~ 
inch steel hypodermic needles and silicone-coated tuberculin syringes. Fifteen minutes after 
the last injection, the size of the lesion was estimated by averaging the widest diameter and the 
diameter perpendicular to it. In most experiments, the results are expressed as the average of 
four guinea pigs. An occasional guinea pig reacted with increased vascular permeability to any 
solution containing human serum proteins. The values obtained in such guinea pigs were not 
included in the data to be presented. 
Human C'1 e3terase,  an enzyme derived from the first component of complement, was pre- 
pared by column chromatography  (22). A euglobulin fraction of fresh human serum was ac- 
tivated to C'1 esterase by incubation at 37°C for 15 minutes at pH 7.4, ionic strength of 0.15, 
applied to a DEAE cellulose column, and einted with a sodium chloride gradient. The active 
enzyme, emerging at ionic strength 0.37, was concentrated and reapplied to a TEAE cellulose 
column at pH 9.0, 0.02 ~ glycine buffer and again eluted with a sodium chloride gradient. On 
some occasions, this  second chromatographic  step  was repeated.  The most highly purified 
preparations, purified 2400-fold with respect to serum and containing 400 units of enzyme per 
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criteria. As was true of cruder preparations of C'I esterase, purified preparations interacted 
with C'4 and C'2 in solution, and were functionally active in hemolytic systems requiring the 
first component of complement (23). Purified C'I esterase lacked detectable activity attributa- 
ble to Hageman factor, as measured in a specific test system (25). 
The activity of C'1 esterase was measured in dtro by microformol titration of the add liber- 
ated from N-acetyl-~-tyrosine ethyl ester during incubation under  standardized  conditions 
(16, 22). One unit of C'I esterase is defined as that amount which liberates 0.5 micromole of 
H + in 15 minutes at 37°C under the conditions of this assay. 
The e~ect of heat upon the esterolytic and permeability-increasing activities of C'1 esterase 
preparations was tested by incubating aliquots of enzyme at indicated temperatures for 30 
minutes. The temperatures recorded are those of the surrounding bath.  Similarly, the effect 
of extremes of pH was studied by titrating aliquots of C'I esterase to the indicated pH values 
with hydrochloric add or sodium hydroxide solutions, and allowing the mixtures to stand at 
room temperature  for 30 minutes.  Samples were then dialyzed against  phosphate-buffered 
saline at 1°C before testing. 
Subcoraponents of C'I were prepared as previously described (26). In essence,  a euglobulin 
fraction of fresh human serum, applied to a  DEAE cellulose column in the presence of tri- 
sodium ethylenediaminetetraacetic add (EDTA), may be resolved into three activities, all of 
which are required for hemolytic C'1 activity and for generation of C'I esterase. The three 
activities have been designated  C'lq, C'lr, and  C'ls. C'lq has been shown to be identical 
with the llS component of Miiller-Eberhard and Kunkel (27) and Taranta, Weiss, and Frank- 
lin (28).  C'lr is a  previously undescribed component, and  C'ls is chromatographically and 
antigenically related to C'1 esterase (26, 29).  Each of these fractions, or any combination of 
two of these fractions, is devoid of C'1 esterase activity, whereas combination of all three 
fractions results in generation of active enzyme. 
Serum inlri,  bitor of C'I esterase (EI), a naturally occurring or-globulin in human serum capa- 
ble of inhibiting the esterolytic and hemolytic activities of C'I esterase stoichiometricaily, was 
purified by colunm chromatography by published procedures (20, 21).  One unit of inhibitor is 
defined as that amount which inhibits 10 units of C'I esterase in the enzymatic assay described 
above (15). The specific activity of the preparation employed was 45 units per optical density 
unit at 280 m#. 
Diisopropylphosphofiuoridate  (DFP)  (Sigma Chemical Company, St. Louis, Missouri) was 
diluted in isopropyl alcohol to a concentration of 2.5 M. Further dilutions were made in 0.12 xf 
sodium bicarbonate solution to the desired concentrations and used at once (30). Solutions of 
DFP were incubated with C'I esterase at 37°C for 30 minutes. Excess DFP was then removed 
by dialysis of the reaction mixture against 2 changes of 200 volumes of phosphate-buffered 
saline solution for 18 to 24 hours at I°C. 
Soy bean trypsin  inhibitor  (SBTD,  5  times crystalline (Nutritional  Biochemicals  Corp., 
Chagrin Falls, Ohio), was suspended in phosphate-buffered saline solution to a concentration 
of 200 micrograms per mi. 
Histamine dipkospkato  (Sigma Chemical Company)  was dissolved in phosphate-buffered 
saline solution. 
The effect of triprolidine  hydrochloride (actidil)  (kindly donated by Burroughs Wellcome 
and  Company,  Tuckahoe,  New York)  upon  the permeability-increasing properties  of  C'I 
esterase was tested by the intravenous administration of 0.1 nag per kg of body weight of the 
test guinea pigs. The triprolidine hydrochloride, a known antihistaminic agent, was adminis- 
tered with the pontamine sky blue dye, before the intracutaneous injection of test substances. 
Histologic sections were prepared from the freshly excised  skin  of a guinea pig which had 
been injected intracutaneously with 0.1  ml of C~I  esterase  (20 units per ml), histamine di- 
phosphate solution (20 micrograms per ml),  and phosphate-buffered saline,  but had not re- 
ceived an injection of pontamine sky blue dye. A series of intracutaneous injections was given 584  COMPLEM~ENT AS MEDIATOR OF IITFL~MM%TION 
at various intervals of time before the animal was sacrificed. The skin was fixed in 10 per cent 
formalin and embedded in paraffin. Sections were stained with hematoxylin and eosin. 
In a  separate  experiment, two  guinea pigs were injected intravenously with 0.8  ml  of 
saccharated iron oxide (proferrin, Merck, Sharpe and Dohme, West  Point, Pennsylvania), a 
dose equivalent to 16 mg of available iron. Within 2 minutes, the animals were injected intra- 
cutaneously into separate sites with 0.1 ml of C'I esterase (40 units per ml), histamine diphos- 
phate (40 micrograms per ml), or buffer. Ten minutes later, the guinea pigs were sacrificed 
and the injected skin sites excised.  Part of the tissue was fixed in 10 per cent formalin, em- 
bedded in paraffin, sectioned, and stained with hematoxylin and eosin or Turnbutl blue-iron 
stain. Remaining portions of tissue were fixed in Caultleld's solution, embedded in methacry- 
late, sectioned on a  Porter-Blum microtome, and observed in an RCA electron microscope. 
Phosphate-bu~ered saline (Dulbecco A) (31) at pH 7.2-7.4 was used as diluent unless other- 
wise noted. 
RESULTS 
1.  The  JPermeability-Increasing Activity  of  Purified  C'1  Esterase.--The 
intracutaneous injection of 0.1  ml of solutions of human C'I esterase at con- 
centrations of 5 units per ml or more increased vascular permeability in the 
guinea pig, as indicated by the increased diameter of the blue area surrounding 
the  point  of injection.  The  appearance  of  the  injected  site  was  strikingly 
similar  to  that  which  followed  the  intracutaneous  injection  of  histamine 
diphosphate solutions. At threshold concentrations, the lesions were pale and 
often showed central pMlor, while at higher concentration, the intensity of the 
blue  color  was  deeper  and  central  pallor  was  often  absent.  Typical dose- 
response curves are shown in Text-figs. 1 to 4; a  comparison with the dose- 
response curve for histamine is shown in Text-fig. 4. 
C'I esterase preparations at various stages of purification were tested. These 
samples  ranged  in  specific activity  (expressed as  units  of  C'I  esterase  per 
optical density unit at 280 m#) from 16 to 400. All preparations tested increased 
vascular  permeability.  Cruder preparations,  however,  were more active per 
\  ° 
unit  of  C'I  esterase  than  purer  preparations,  although  the  purest  fraction 
tested had significant activity at a level of 1 microgram of protein in the injec- 
tion site. Two interpretations of these observations were possible: either the 
permeability-increasing activity of purified C'I esterase was due entirely to a 
contaminating  permeability factor  or  extraneous  permeability  factors  were 
present in the cruder preparations, enhancing the effect of C'I esterase itself. 
Experiments  to  differentiate  these  possibilities  form  the  substance  of  this 
paper. 
2.  The  Effects  of Serum Inhibitor  of C'1  Esterase and  Soy  Bean  Trypsin 
Inhibitor.--Purified  Cq  esterase was incubated at 37°C for 10 minutes  with 
amounts of purified serum inhibitor of C'I esterase (El) in such concentration 
as to inhibit 25, 50, 75, and 100 per cent of the available enzyme. When various 
dilutions of these mixtures were injected intracutaneously into  guinea pigs, 
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content of C'I esterase but rather to the residual concentration of free enzyme 
(Text-fig. 1). For example, if 50 units of C'1 esterase were treated with 5 units 
of serum inhibitor of C'I  esterase  (stoichiometric equivalence), neither free 
enzyme nor permeability-increasing activity remained. At lesser concentrations 
of inhibitor, the permeability-increasing property of the mixtures was similar 
to that  of untreated preparations  of C'I  esterase  of comparable esterolytic 
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T~xT-Fm. 1. Inhibition of C'I esterase by serum inhibitor of C'I esterase, and lack of in- 
hibition by soy bean trypsin inhibitor: Correlation between residual esterolytic activity and 
permeability-enhancing activity. The abscissa represents the actual  concentrations of free 
C'1 esterase in the test solutions. Various amounts of serum inhibitor of C'1 esterase (EI) were 
incubated with a  fixed amount of enzyme to achieve various levels of inhibition. The curve 
demonstrates the permeability-increasing  activity of the mixtures as a function of the residual 
free esterase in the inhibited mixtures. Various amounts of C'1 esterase were incubated with 
soy bean trypsin inhibitor (SBTI) at a concentration  of 100/~g per ml. No inhibition  of estero- 
lytic or permeability-increasing  activities occurred. The curve demonstrates this correlation. 
activity.  The  figure  depicts  the  correlation  between  res/dual  C'1  esterase 
activity and permeability-increasing activity. 
Similar experiments were performed with soy bean trypsin inhibitor (SBTI), 
an agent without effect on the esterolyfic property of C'1 esterase  (10)  but 
known  to  inhibit  the  permeability-increasing  properties  of  diluted  human 
plasma (PF/Dil) (32) and of activated Hageman factor (33). Soy bean trypsin 
inhibitor at a concentration of 100 micrograms per mt had no detectable inhibi- 
tory effect either on the esterolytic or permeability-increasing effects of prepara- 
tions of C'1 esterase. The correlation between these activities in the presence 
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3.  The  Effect  of  Diisopropylphosphofluoridate.--Purified  C'I  esterase  was 
treated with DFP at concentrations of 10  -2, 10  -a, 10  -4, and 10  -~ ~r, resulting in 
100, 97,  30,  and  11  per  cent inhibition of esterolytic activity, respectively. 
DFP inhibited the permeability-enhancing activity of C'I esterase as well, the 
extent of inhibition being proportional to the loss of esterolytic activity (Text- 
fig. 2). Thus, the permeability-enhancing activity after removal of excess DFP 
was equivalent to that of untreated enzyme of comparable esterolytic activity. 
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TEXT-FIG.  2. Inhibition of C'l esterase by diisopropylphosphofluoridate (DFP): Correla- 
tion between residual esterolytic activity and permeability-enhancing activity. A solution of 
C'I esterase containing 55 units/nil was incubated with various concentrations of DFP for 30 
minutes and then dialyzed. The curve demonstrates the permeability-increasing activity of 
DFP-treated  C'I  esterase as a  function of residual active enzyme,  each preparation being 
tested at several dilutions. The permeability-increasing activity is proportional to the estero- 
lyric activity remaining after DFP treatment. 
4.  The Effect of Heat and pH.--Puritied Cq esterase is relatively more stable 
at elevated temperatures than cruder preparations (22). Thus, incubation of a 
highly purified preparation  for 30  minutes at 56°C  resulted in 67  per  cent 
inactivation; at 80°C, in 61 per cent inactivation; and at 100°C, in 99 per cent 
inactivation.  Again,  the  permeability-increasing  activities  of  the  heated 
preparations were proportional to residual enzyme concentration and equivalent 
to that of untreated enzyme tested at the same concentrations (Text-fig. 3). 
Similarly 92 per cent of the esterolytic activity was inactivated by treatment 
of C'I esterase at pH 3.8,  and 36 per cent was inactivated at pH 11.0;  these 
procedures  also  failed  to  dissociate  esterolytic  and  permeability-enhancing 
activities (Text-fig. 3). OSCAR D.  RATNOFF  AND  IRWIN  H.  LEPOW  687 
5. Generation of C'I  Esterase and Permeability-Enhancing Activities from 
Subcomponents of C'l.--Partially  purified  preparations  of  C'lq,  C'lr,  and 
C'ls  were  tested  individually,  and  in combinations  of  two or all  three  for 
esterolytic and permeability-increasing activities. As reported previously, only 
the combination of C'lq,  C'lr,  and C'ls resulted in generation of C'I esterase 
(26).  Moreover,  in  contrast  to  other  mixtures,  this  combination  possessed 
marked permeability-increasing activity (Table I). The permeability-increas- 
ing property could be inhibited by a stoichiometric amount of purified  serum 
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TEXT-FIG.  3. The effect of heat and pH upon the esterolytic and vascular permeability 
increasing properties of C'I esterase. As in the previous figures, the permeability-increasing 
property of C'I esterase is plotted as a  function of the residual C~I  esterasc activity after 
treatment with heat or extremes of pH. 
inhibitor of C'I esterase.  The activity generated was similar  to that achieved 
by comparable concentrations of purified  C'I esterase. C'lq and C'lr each had 
slight permeability-increasing activity, but only when tested at concentrations 
greater than in the mixture of C'lq, C'lr, and C'ls. 
5.  The Effect of Intravenously Injected Triprolidir~ upon the Permeability- 
Enhancing Property of C'I Esterase.--One way in  which  C'I  esterase might 
increase vascular permeability might be to induce the local release of histamine 
or a  histamine-like  substance.  The  gross appearance  of the area of blueing 
provoked by C'I esterase was similar  to that which followed the injection of 
histamine.  It  was  therefore  of  interest  to  test  the  effect  of  a  known 
antihistaminic  agent, triprolidine hydrochloride. The intravenous injection of 
0.1  mg  of  this  substance  per  kg  of  body  weight  inhibited  the  vascular 688  COMPLEMENT  AS  MEDIATOR  OF  INFLAMMATION 
permeability-increasing property of C'I esterase and of histamine diphosphate 
(Text-fig. 4 and Fig. 1). This effect was highly significant, the extent of inhibi- 
tion of the permeability-increasing activity of C'1 esterase by triprolidine being 
16-fold.  In  vitro,  however,  triprolidine  was  without  effect  on the  esterolytic 
activity of C'1 esterase, even when tested at a  concentration of 2 mg per ml. 
TABLE I 
Generation ~C'lEsteraseandPermeability-En~mingActi~ty~om S~compon~ts~ C'1 
Mixture tested 
I. Subcomponents of C'I 
1 part C'lq +  1 part buffer 
1 part Cqr +  1 part buffer 
1 part C'ls +  1 part buffer 
1 part C'lq +  1 part C'lr 
1 part C'lq +  1 part C'ls 
1 part Cqr +  1 part C'ls 
0.5 part C'lq +  0.5 part C'lr +  1 part C'ls 
II. Purified C'I esterase 
III. Phosphate-buffered saline solution 
Permeability activity 
Dilution tested  Diameter 
of lesion 
Undiluted  5.1 
Diluted ~  3.9 
Diluted ~  4.4 
Undiluted  6.1 
Undiluted  5.0 
Undiluted  5.9 
Diluted  ~  4.6 
Diluted ~  3.6 
Undiluted  4.0 
Diluted ~  5.0 
Diluted ~  3.8 
Undiluted  5.0 
Undiluted  9.0 
Diluted ~  8.2 
Diluted ~  6,5 
Diluted ~  5.2 
8.4 
9.1 
7.4 
4.4 
Undiluted  3.6 
7.  The  Duration  of  Action  of  Intracutaneously  Injected  C'1  Esterase  and 
Histamine.--Pontamine  sky blue was injected  intravenously into guinea pigs 
which  had  been  injected  intracutaneously  with  C'1  esterase  and  histamine 
diphosphate at time intervals ranging from 0 to 30 minutes before the adminis- 
tration  of  dye.  The  effect  of  both  substances  was  evanescent,  decreasing 
significantly within 10 minutes after injection (Text-fig. 5). 
8.  ttistotogic Examination of Skin Sites Injected with C'I Esterase,  Histamine, 
or  Buffer.--Hematoxylin  and  eosin-stained  paraffin  sections  of  skin  sites OSCAR D. KATNOI~F AND  IRWIN W. LEPOW  689 
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TEx¢-Fzo.  4.  The effect of triprolidine on the permcability-incrcasing properties of C'I 
esterase and  histamine.  Guinea pigs  were  injected intravenously with  triprolidine hydro- 
chloride, 1 mg per kg of body weight, or with saline solution. C'1 esterase and histamine di- 
phosphate were then injected intracutaneously in the concentrations indicated on the abscissa. 
The size of the resultant lesions is plotted on the ordinate. 
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C'l esterase (20 units/ml) or histamine (20 #g/ml) was injected at indicated intervals of time 
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excised at various times from immediately to 4 hours after the intracutaneous 
injection of C'I esterase (20 units per ml), histamine diphosphate (20 ~g per ral), 
or buffer revealed only subtle  pathological  alterations. Both the enzyme and 
histamine sites had a greater number of polymorphonuclear leukocytes aggre- 
gated in vascular spaces and free in the surrounding tissue  and an increased 
incidence  of separation of collagen fibers, as compared  with buffer  controls. 
The differences, however, were not marked. 
A  more  convincing  histologic  demonstration  of  the  pathophysiological 
abnormality induced by C'I esterase was provided by use of saccharated iron 
oxide as a marker. Skin sites from guinea pigs which had received 16 nag of iron 
equivalent intravenously  were excised 10 minutes after intracutaneous injection 
of 0.1 ml of C'I esterase  (40 units per ml), histamine diphosphate (40 #g per 
ml), or buffer. Closely adjacent paraffin sections were stained with hematoxylin 
and eosin or TurnbuU blue-iron stain (Figs. 2 a and 2 b). The iron stain revealed 
the presence of iron in and immediately surrounding the walls of small vessels. 
This finding was striking and involved many small vessels in skin sites which 
had received enzyme or histamine but was detectable only in the immediate 
area  of the needle  tract in buffer  controls.  The caliber  and  type of vessel 
affected were consistent with postcapillary venules,  reported by Majno and 
Palade (34) to be the target organ for the permeability-enhandng activity of 
histamine. 
Specimens of skin from the above experiment  were also fixed in Caulfield's 
solution,  embedded in methacrylate, and examined  with the electron  micro- 
scope (Figs. 3 and 4). The findings confirmed and extended those obtained by 
optical  microscopy.  In skin sites  which  had received  C'I esterase,  iron was 
visualized  in endothelial junctions and at the basement membrane of small 
vessels, compatible  in appearance with postcapillary venules.  Large amounts 
of iron were also observed on the pericyte side of the basement membrane. Iron 
was not found in the vesicles of endothelial cells. The same pattern of distribu- 
tion of iron was noted in skin sites which had received histamine. The latter 
observations  were in accordance with those of Majno and Palade (34). 
DISCUSSION 
Many mechanisms  have been  invoked to explain  the increase  in vascular 
permeability which is an important element in the reaction of tissues to injury. 
These proposed mechanisms are based in common upon the assumption that a 
chemical agent is either generated at the site of injury or released preformed 
from some loose combination.  For example, the local release of histamine or a 
histamine-like  substance  (35), 5-hydroxytryptamine (36), and  certain poly- 
peptides  (37-39) has been  thought to contribute  to the increase  in vascular 
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Considerable information exists concerning the participation of plasma in increasing 
vascular permeability. Thus, homologous or certain heterologous  plasmas,  diluted 
with saline solution  in glass tubes,  evolve the capacity to enhance vascular perme- 
ability in guinea pig skin (24). The agent responsible for the enhancement of perme- 
ability, designated  PF/I)il or globulin permeability factor by Miles, is ~nMbited by 
treating the plasma with diisopropylphosphofluoridate  or by the simultaneous  local 
injection of soy bean trypsin inhibitor,  but not by the intravenous injection of anti- 
histaminic  compounds (32). PF/DIl is thought to be a hydrolytic enzyme. 
A second permeability-increasing  property of human plasma can be demonstrated 
by its intracutaneous injection undiluted into guinea pig skin (40). This "PF/Nat" 
is not antagonized  by local soy bean trypsin inhibitor or by systemic antihistaminic 
agents.  The nature of PF/Nat is not yet elucidated,  though Elder and Wilhelm (40) 
suggested that this factor may be related to that property of human plasma which 
may produce necrosis in guinea pig skin (41). 
A third possible permeability factor may evolve in plasma under experimental con- 
ditions. Plasma contains an inactive agent, k~nikreinogen, which can be activated by 
several  means  to form kallikrein,  a  substance  with enzyme-like properties (42). In 
turn, kallikrein releases at least two biologically active polypeptide "plasma klnins," 
bradykinin (kallidin I) and kallidin  (kallidin II) from a precursor in plasma glob,lHn 
(43, 44). Among their other properties, these polypeptides increase vascular perme- 
ability in guinea pig skin (39, 45, 46). Kallikrein, too, increases vascular permeability, 
presumably through the production of plasma  k~n~ns. The permeability-enhancing 
activity of bradykinin is not affected by soy bean trypsin inhibitor, while that of 
kallikrein,  its liberator, is inhibited (46). In all likelihood, PF/Dil and kallikrein  are 
not identical (47), though PF/DIl may function as an activator of kalHkreinogen (48). 
Another possible permeability factor is said to be released from undiluted guinea 
pig serum upon incubation with insoluble antigen-antibody aggregates  (2). The re- 
lease of the permeability-increasing  property does not seem to be related to the forma- 
tion of PF/DIl or plasma  kinins,  nor is its activity significantly inhibited by anti- 
histaminic  agents. Whether the activity studied by Davies and Lowe can be ascribed 
to the elaboration of anaphylatoxin is not clear. Anaphylatoxin refers to the toxic 
agent or agents which appear in guinea pig (3, 49) or rat (50) sera treated with such 
diverse agents as antigen-antibody aggregates, polysaccharides, and polyvinyl pyrroli- 
dine. Among its other described properties, anaphylatoxin is said to increase vascular 
permeability and contract smooth muscle. Anaphylatoxin may exert at least part of 
its effect by releasing histamine-like activity in tissue (51). Antihistaminic  drugs block 
its effect (52). 
The studies described in the present report suggest that human plasma may 
contain  the  precursor  of  still  another  factor  which  may increase  vascular 
permeability  in  guinea  pig  skin.  The  intracutaneous  injection  of  purified 
preparations  of  the  esterase  derived  from  the  first  component  of  com- 
plement regularly enhanced vascular permeability. The effect of C'1  esterase 
was inhibited by pretreatment with a naturally occurring serum inhibitor of this 
enzyme or with DFP, but not by soy bean trypsin inhibitor. Moreover, treat- 692  COMPLEMENT  AS  MEDIATOR  OF  Ilq'FL/~MMATION 
ment of C'1 esterase by heat or extremes of pH inactivated its esterolytic and 
permeability-enhancing  properties  in  parallel.  The  permeability-enhancing 
activity was a function of activated C~I esterase; its inactive precursor  (C'ls) 
had no demonstrable effect, but permeability-increasing  activity was generated 
pari passu with esterolytic activity when CPls was incubated with C'lq and 
Cqr, both of which are needed for its activation (26). 
The mechanism through which  activated C'I  esterase  increased  vascular 
permeability is not yet dear. The preparations tested were devoid of activated 
Hageman factor, a blood clotting factor which increases vascular permeability 
by activating PF/Dil  (53, 54). The lack of inhibition by soy bean  trypsin 
inhibitor distinguished  C'I esterase from PF/Dil (32) and from kallikrein (55). 
The data presented are compatible with the view that activated C'I esterase 
releases  a  histamine-like  substance  within  guinea  pig  skin.  Intravenously 
injected triprolidine,  an antihistaminic compound,  dramatically inhibited the 
effect of Cq esterase, in contradistinction to its ineffectiveness against PF/Nat, 
PF/Dil, kallikrein, plasma kinins, and the factor released by antigen-antibody 
aggregates described by Davies and Lowe (2). The appearance of the blue spots 
produced by the injection of Cq esterase in guinea pigs injected with pontamine 
sky  blue  was  similar  in  the  gross  to  that  produced  by  histamine.  The 
evanescence  of  the  increase  in  vascular  permeability  which  followed  the 
injection of Cq  esterase  resembled  that which followed histamine, but  the 
duration of increased vascular permeability is by no means specific (32). The 
histologic and electron microscopic nature of the changes produced were also 
similar to those of histamine but again were non-specific. 
These observations do no more than to suggest a possible relationship between 
Ctl  esterase  and  the release  of histamine. Incubation of  C'I  esterase  with 
guinea pig lung (56) or rat peritoneal mast cells (57) in the presence or absence 
of normal serum did not release histamine under the conditions employed (58). 
In these experiments, the test system was highly reactive to appropriate antigen 
or antibody. Whether in fact histamine-like  activity might be evoked by C'I 
esterase in other situations remains to be determined. 
The relationship between the permeability-increasing  activity of C'I esterase 
and several  other conditions  must be considered.  Mention has already been 
made of the enhancement of vascular permeability by anaphylatoxin. Studies 
by Osler and his associates  (59) have demonstrated that anaphylatoxins are 
elaborated  in  rat  serum  treated  with  antigen-antibody aggregates  only if 
complement is present, as postulated many years before by Friedberger  (3) and 
Friedemann  (49). Although Osler emphasized  the  importance  of  the  third 
component of complement in the elaboration  of anaphylatoxin, his studies are 
compatible  with an earlier role for C'I esterase in the phenomenon. 
The intraperitoneal injection of fresh  human plasma provokes  peritoneal 
exudation in rats  (7). How this heterologous  plasma induces  increased  per- OSCAR  D.  RATNO]?]?  AND  IRWIN  H.  LEPOW  693 
meability  in  the  vessels  lining  the  peritoneal  cavity  is  not  known,  but 
Greisman's  experiments  suggest the participation  of complement.  A  specific 
role for Crl esterase was not delineated. 
Passive  cutaneous  anaphylaxis,--  a  phenomenon  in which  local  vascular 
permeability is enhanced by the intracutaneous injection of specific antibody to 
an  animal  which  has  been  injected  intravenously with  antigen,--  may  be 
inhibited by antihistaminic agents (1). None the less, whether histamine has a 
role in passive cutaneous anaphylaxis is disputed (60, 61). Experiments have 
been described in which complement, particularly the third component, appears 
to participate in passive cutaneous anaphylaxis in the rat (5), but the role of 
complement has been disputed on the basis of recent evidence (6 a). 
Finally  the  possible participation  of  C'1  esterase  in  the  pathogenesis  of 
attacks of hereditary angioneurotic edema is intriguing.  In this disorder the 
patient  suffers  repeated attacks  of severe,  localized  edema involving partic- 
ularly the skin, gastrointestinal tract, and larynx. The serum of such individuals 
lacks detectable amounts of the inhibitor of C'1 esterase normally present (62, 
63). Moreover, during a bout of edema, free C'1 esterase may be found in the 
patient's serum (64). It is tempting to relate the episodes of edema, presumably 
the result of locally increased vascular permeability, to the unopposed release 
of  Ctl  esterase.  However, Landerman  and  coworkers  (65)  have  reported  a 
deficiency  of serum inhibitor  of kallikrein  in patients  with hereditary anglo- 
neurotic edema and Kagan and Becket (66) have shown that purified  serum 
inhibitor of C~1 esterase will block the activities of PF/Dil and kallikrein.  The 
precise mechanism of edema formation in this genetically determined disease is 
therefore not yet clear. 
The observations which we have recorded represent the first known in vi$'o 
effect  of  Ctl  esterase  per  se.  The  mechanism  of  enhancement  of  vascular 
permeability by C'1 esterase and its role in initiation of inflammation in man 
remain to be explored. 
SUMMARY 
Purified preparations  of the esterase derived from the first component of 
complement (Ctl esterase) increased vascular permeability in guinea pig skin, 
an  effect inhibited  by triprolidine,  an antihistaminic  agent,  but not by soy 
bean trypsin inhibitor.  The permeability-increasing and esterolytic properties 
of C'1 esterase were inhibited in parallel by the serum inhibitor of C~1 esterase, 
diisopropylphosphofluoridate and extremes of temperature and pH. Moreover, 
the permeability-increasing and esterolytic properties evolved in parallel when 
C'1 esterase was generated from its subcomponents. How Crl esterase induces 
changes  in  vascular  permeability  remains  unexplained,  although  the  pos- 
sibility that its action is mediated through a histamine-like agent is attractive. 694  COMPLEMENT AS  MEDIATOR OF  INFLAMMATION 
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EXPLANATION OF PLATES 
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FIG.  1.  The  effect of triprolidine on the permeability-increasing property of C'l 
esterase. The photograph on the bottom is of an animal injected intravenously with 
triprolidine, 0.1 mg per kg of body weight, and that on the top of an animal injected 
intravenously with saline solution. The animals were injected intracutaneously with 
0.1  ml of solutions of Crl esterase containing 40, 20, 10, and 5 units per ml, reading 
from left to right in each case. This photograph demonstrates not only the inhibition 
of the reaction by triprolidine, but also the halo-like appearance of the lesion pro- 
duced by the smaller amounts of C'l esterase. Each division of the scale on the right 
is 1 mm. 
FIGS. 2 a  and 2 b. Histologic appearance of guinea pig skin after the intravenous 
injection of saccharated iron oxide and the intracutaneous injection of C'1 esterase. 
X  300.  Fig. 2 a. Hemotoxylin and eosin stain. Fig. 2 b. Turnbull blue-iron stain. In 
this photograph, iron-containing material appears black. The selective effect of Cq 
esterase for vessels compatible in appearance with postcapillary venules is illustrated. 
Iron is not present in the artery (A) in the upper left hand portion of the photograph 
or in the two capillary-size vessels (C). In contrast, many of the small vessels of the 
size of postcapillary venules contain iron. 'rite  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL. 118  PLATE  77 
(Ratnoff and Lepow: Complement as mediator of inflammation) PLATE 78 
FIG. 3.  Electron micrograph of a  small blood vessel in guinea pig skin after the 
intravenous injection of saccharated iron oxide and  the  intracutaneous injection of 
C'I esterase. Two erythrocytes are present in the lumen. The following symbols are 
used: E  (endothelial cells), J  (junction between endothelial cells), B  (basement mem- 
brane),  P  (pericyte), CT  (connective tissue), and  I  (saccharated iron oxide). Iron 
can  be  seen  in  the  junction,  J,  and  at both sides of the basement membrane, B. 
×  16,300. THE JOURNAL  OF EXPERIMENTAL  MEDICINE  VOL. 118  PLATE  78 
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FIG. 4. Electron micrograph of a portion of a small vessel similar to that shown in 
Fig. 3. In addition to the symbols used in Fig. 3, the following appear: L (lumen) and 
V (vesicle).  Iron can be seen in the junction, J,  but is absent in the cytoplasm on 
cytoplasmic vesicles,  V, of endothelial cells.  X 46,900. TIlE  JOURNAL  OF  EXPERIMENTAL  ]Y~EDICINE VOL. 118  PLATE 79 
(Ratnoff and Lepow: Complement as mediator of inflammation) 